Index RUT P/E - EPS (ttm) -1.64 Insider Own 70.06% Shs Outstand 43.59M Perf Week 29.27%
Market Cap 385.26M Forward P/E - EPS next Y -0.77 Insider Trans -1.42% Shs Float 19.07M Perf Month 63.96%
Income -60.18M PEG - EPS next Q -0.14 Inst Own 37.36% Short Float 2.10% Perf Quarter 55.13%
Sales 0.00M P/S - EPS this Y 76.15% Inst Trans 2.60% Short Ratio 1.28 Perf Half Y 38.44%
Book/sh 1.40 P/B 4.32 EPS next Y -53.98% ROA -76.37% Short Interest 0.40M Perf Year 13.94%
Cash/sh 1.41 P/C 4.29 EPS next 5Y - ROE -115.90% 52W Range 2.00 - 13.00 Perf YTD 29.55%
Dividend Est. - P/FCF - EPS past 5Y - ROI -98.64% 52W High -53.46% Beta 0.35
Dividend TTM - Quick Ratio 6.17 Sales past 5Y 0.00% Gross Margin - 52W Low 202.50% ATR (14) 0.47
Dividend Ex-Date - Current Ratio 6.17 EPS Y/Y TTM -867.93% Oper. Margin 0.00% RSI (14) 79.65 Volatility 11.72% 11.78%
Employees 15 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 17.80
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q 99.43% Payout - Rel Volume 1.41 Prev Close 6.00
Sales Surprise - EPS Surprise 91.40% Sales Q/Q - Earnings May 09 BMO Avg Volume 313.97K Price 6.05
SMA20 37.59% SMA50 71.65% SMA200 28.75% Trades
Volume 439,335 Change 0.83%
Date
Action
Analyst
Rating Change
Price Target Change
May-03-24 Initiated Piper Sandler
Overweight
$26
Oct-10-23 Initiated Ladenburg Thalmann
Buy
$10
Aug-25-23 Initiated Oppenheimer
Outperform
$17
Jun-22-23 Initiated Guggenheim
Buy
$20
Jun-14-23 Initiated Chardan Capital Markets
Buy
$14
May-24-23 Initiated Raymond James
Strong Buy
$20
May-15-24 09:55AM
May-14-24 12:00PM
May-12-24 03:26PM
May-10-24 03:14PM
May-09-24 01:56PM
06:00AM
Loading…
06:00AM
Apr-25-24 02:18AM
Apr-18-24 09:22AM
Apr-08-24 06:00AM
Mar-28-24 11:54AM
06:00AM
Mar-04-24 06:00AM
Feb-02-24 06:00AM
Jan-08-24 06:00AM
Jan-03-24 06:00AM
06:00AM
Loading…
Dec-04-23 06:00AM
Nov-14-23 06:00AM
Nov-13-23 06:30AM
Sep-12-23 05:00AM
Sep-05-23 08:55PM
Aug-25-23 09:42AM
Aug-14-23 07:00AM
Jun-23-23 06:30AM
Jun-06-23 06:34AM
04:00AM
Jun-01-23 10:20AM
Apr-27-23 07:39AM
Apr-14-23 05:00AM
Mar-27-23 09:35AM
Mar-21-23 06:13AM
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sidhu Someit Director Apr 22 '24 Buy 3.13 1,186,901 3,715,000 1,186,901 Apr 24 06:51 PM Munshi Amit Director Apr 22 '24 Buy 3.13 159,744 499,999 777,384 Apr 24 06:52 PM Howell Michael See Remarks Apr 22 '24 Buy 3.13 7,987 24,999 7,987 Apr 24 06:54 PM Nistala Kiran Executive Vice President Apr 22 '24 Buy 3.13 3,195 10,000 3,195 Apr 24 06:53 PM Thiara Parvinder Director Dec 12 '23 Sale 4.00 2,000,000 8,000,000 4,801,633 Dec 14 03:35 PM Munshi Amit Director Jun 05 '23 Buy 4.25 117,647 500,000 617,640 Jun 05 07:15 PM
Index - P/E - EPS (ttm) -6.50 Insider Own 39.82% Shs Outstand 20.34M Perf Week 3.72%
Market Cap 385.78M Forward P/E - EPS next Y -3.06 Insider Trans 1.04% Shs Float 15.44M Perf Month -3.96%
Income -47.97M PEG - EPS next Q -0.69 Inst Own 63.84% Short Float 20.13% Perf Quarter -64.74%
Sales 0.00M P/S - EPS this Y 68.51% Inst Trans -7.46% Short Ratio 7.24 Perf Half Y -6.64%
Book/sh 10.08 P/B 1.49 EPS next Y -9.67% ROA -18.04% Short Interest 3.11M Perf Year -41.48%
Cash/sh 13.66 P/C 1.10 EPS next 5Y - ROE -18.60% 52W Range 9.18 - 48.31 Perf YTD -42.55%
Dividend Est. - P/FCF - EPS past 5Y -19.23% ROI -23.37% 52W High -68.87% Beta 2.37
Dividend TTM - Quick Ratio 41.76 Sales past 5Y 0.00% Gross Margin - 52W Low 63.83% ATR (14) 1.21
Dividend Ex-Date Oct 20, 2023 Current Ratio 41.76 EPS Y/Y TTM 65.52% Oper. Margin 0.00% RSI (14) 33.30 Volatility 6.13% 5.95%
Employees 52 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 58.33
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q 89.73% Payout - Rel Volume 0.43 Prev Close 15.00
Sales Surprise - EPS Surprise 17.70% Sales Q/Q - Earnings May 13 BMO Avg Volume 429.18K Price 15.04
SMA20 -2.39% SMA50 -35.61% SMA200 -42.32% Trades
Volume 184,989 Change 0.27%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-15-23 Initiated Jefferies
Buy
$41
Dec-04-23 Resumed H.C. Wainwright
Buy
$48
Nov-17-23 Initiated Truist
Buy
$43
Oct-31-23 Initiated Guggenheim
Buy
$50
Oct-25-23 Initiated Piper Sandler
Overweight
$65
Oct-20-22 Initiated H.C. Wainwright
Buy
$18
Jul-05-22 Downgrade Morgan Stanley
Overweight → Equal-Weight
$20 → $8
May-16-24 07:00AM
May-13-24 01:54PM
07:00AM
Apr-02-24 07:00AM
Mar-19-24 02:52PM
07:00AM
Loading…
07:00AM
Mar-15-24 08:50AM
Feb-28-24 08:50AM
Feb-27-24 07:30AM
Feb-08-24 08:50AM
Feb-01-24 08:00AM
Jan-29-24 04:01PM
Jan-25-24 07:00AM
Jan-24-24 04:05PM
Jan-08-24 07:00AM
04:00PM
Loading…
Dec-15-23 04:00PM
Dec-14-23 07:30AM
Nov-01-23 08:00AM
Oct-26-23 09:02PM
Oct-19-23 05:37PM
Oct-17-23 05:47PM
Oct-06-23 05:09PM
Oct-04-23 08:30AM
Jun-22-23 07:30AM
May-26-23 07:00AM
May-20-23 08:18AM
Feb-16-23 03:10PM
(American City Business Journals) +24.05%
07:00AM
Dec-25-22 09:25AM
Nov-22-22 07:00AM
07:00AM
Loading…
Nov-10-22 07:00AM
Nov-07-22 07:00AM
Oct-21-22 11:28AM
Oct-20-22 02:27PM
10:26AM
08:24AM
07:00AM
Oct-17-22 07:00AM
Oct-04-22 07:00AM
Sep-21-22 07:00AM
Sep-06-22 07:00AM
Aug-15-22 07:00AM
Jul-18-22 09:47AM
Jun-30-22 07:00AM
Jun-07-22 04:01PM
Jun-01-22 07:00AM
May-31-22 07:00AM
May-17-22 04:01PM
07:00AM
May-12-22 04:01PM
May-02-22 07:00AM
Apr-28-22 11:45AM
Apr-06-22 04:01PM
Mar-22-22 04:01PM
Mar-17-22 04:01PM
Feb-11-22 07:00AM
Feb-08-22 01:32PM
Jan-31-22 09:38AM
Jan-06-22 07:00AM
Jan-04-22 07:00AM
Dec-20-21 07:00AM
Dec-14-21 07:00AM
Nov-30-21 07:00AM
Nov-12-21 07:00AM
Nov-08-21 07:00AM
Nov-04-21 06:00AM
Oct-29-21 07:00AM
Oct-28-21 04:36PM
Sep-02-21 07:00AM
Aug-12-21 07:00AM
Aug-10-21 08:10AM
Jun-14-21 04:01PM
Jun-03-21 07:00AM
May-11-21 04:01PM
May-06-21 09:53PM
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MCDADE MARK Director Jan 29 '24 Buy 32.50 100,000 3,250,000 448,431 Jan 31 04:26 PM Kulkarni Sandeep Chidambar CEO Nov 17 '23 Buy 16.99 4,000 67,960 729,735 Nov 20 06:15 PM Thiara Parvinder Director Nov 17 '23 Buy 17.31 1,000 17,310 83,782 Nov 20 06:14 PM Castelein Caley Director Oct 27 '23 Buy 14.55 15,800 229,890 516,519 Oct 27 05:43 PM Kulkarni Sandeep Chidambar CEO Oct 26 '23 Buy 12.25 5,000 61,250 725,735 Oct 26 05:34 PM Castelein Caley Director Oct 25 '23 Buy 12.07 4,200 50,694 500,719 Oct 27 05:43 PM Thiara Parvinder Director Oct 25 '23 Buy 12.12 2,000 24,240 82,782 Oct 26 04:46 PM KANTOFF AARON Director Oct 24 '23 Buy 11.86 7,500 88,950 45,391 Oct 26 05:00 PM Thiara Parvinder Director Oct 24 '23 Buy 10.66 5,000 53,300 80,782 Oct 26 04:46 PM Kulkarni Sandeep Chidambar CEO Oct 24 '23 Buy 10.68 4,650 49,662 720,735 Oct 26 05:34 PM Ildstad Suzanne Director Jun 14 '23 Sale 2.49 12,942 32,244 3,771,392 Jun 14 06:58 PM Ildstad Suzanne Director Jun 13 '23 Sale 2.56 14,208 36,338 3,784,334 Jun 14 06:58 PM Ildstad Suzanne Director Jun 12 '23 Sale 2.59 16,870 43,725 3,798,542 Jun 14 06:58 PM Ildstad Suzanne Director Jun 09 '23 Sale 2.46 25,419 62,637 3,815,412 Jun 09 05:41 PM Ildstad Suzanne Director Jun 08 '23 Sale 2.48 40,642 100,772 3,840,831 Jun 09 05:41 PM Ildstad Suzanne Director Jun 07 '23 Sale 2.39 75,001 179,095 3,881,473 Jun 09 05:41 PM Ildstad Suzanne Director Jun 06 '23 Sale 2.53 25,549 64,596 2,756,474 Jun 07 06:24 PM Ildstad Suzanne Director Jun 05 '23 Sale 2.52 7,841 19,755 2,782,023 Jun 07 06:24 PM Ildstad Suzanne Director Jun 02 '23 Sale 2.50 15,818 39,616 2,789,864 Jun 05 04:21 PM Ildstad Suzanne Director Jun 01 '23 Sale 2.56 15,713 40,177 2,805,682 Jun 05 04:21 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
